Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Gastric Cancer | Research

Tumor size as a significant prognostic factor in T1 gastric cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis

Authors: Xueyan Xiao, Beibei Gao, Suya Pang, Zeyu Wang, Weiwei Jiang, Weijun Wang, Rong Lin

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

It has previously been observed that the prognostic value of tumor size varied according to different stages patients enrolled in gastric cancer. We aimed to investigate the influence of T stage on the prognostic and predicting value of tumor size.

Material and methods

A total of 13,585 patients with stage I–III gastric cancer were selected from the Surveillance, Epidemiology, and End Results Program (SEER) database. Univariate and multivariate cox regression analysis stratified by T stage were performed. C-index and time-dependent receiver operating characteristic curve (ROC) curve were applied to assess discrimination ability of tumor size and other factors. Nomograms were constructed to further assess the performance of tumor size in a specific model. Calibration ability, discrimination ability, reclassification ability and clinical benefits were executed to judge the performance of models.

Results

Stratified analyses according to T stage illustrated that with the increase of T stage, the effect of tumor size on overall survival (OS) and cancer-specific survival (CSS) significantly decreased. Moreover, tumor size showed superior discrimination ability in T1 gastric cancer, outperformed other prognostic factors in predicting both CSS (C-index: 0.666, AUC: 0.687) and OS (C-index: 0.635, AUC: 0.660). The cox regression model included tumor size showed better performance than the model excluded tumor size in every aspect.

Conclusion

T stage had a negative impact on the predicting value of tumor size. Tumor size showed significant prognostic value in T1 gastric cancer, which may be effective in clinical practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48.CrossRefPubMed Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48.CrossRefPubMed
2.
go back to reference Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75.CrossRefPubMedPubMedCentral Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75.CrossRefPubMedPubMedCentral
3.
go back to reference Amin MBES, Greene FL, et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2016. Amin MBES, Greene FL, et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2016.
4.
go back to reference Lin JX, Desiderio J, Lin JP, Wang W, Tu RH, Li P, et al. Multicenter Validation Study of the American Joint Commission on Cancer (8th Edition) for Gastric Cancer: Proposal for a Simplified and Improved TNM Staging System. J Cancer. 2020;11(12):3483–91.CrossRefPubMedPubMedCentral Lin JX, Desiderio J, Lin JP, Wang W, Tu RH, Li P, et al. Multicenter Validation Study of the American Joint Commission on Cancer (8th Edition) for Gastric Cancer: Proposal for a Simplified and Improved TNM Staging System. J Cancer. 2020;11(12):3483–91.CrossRefPubMedPubMedCentral
5.
go back to reference Bando E, Ji X, Kattan MW, Seo HS, Song KY, Park CH, et al. Development and validation of a pretreatment nomogram to predict overall survival in gastric cancer. Cancer Med. 2020;9(16):5708–18.CrossRefPubMedPubMedCentral Bando E, Ji X, Kattan MW, Seo HS, Song KY, Park CH, et al. Development and validation of a pretreatment nomogram to predict overall survival in gastric cancer. Cancer Med. 2020;9(16):5708–18.CrossRefPubMedPubMedCentral
6.
go back to reference Dai W, Mo S, Xiang W, Han L, Li Q, Wang R, et al. The critical role of tumor size in predicting prognosis for T1 colon cancer. Oncologist. 2019;25(3):244–51.CrossRefPubMedPubMedCentral Dai W, Mo S, Xiang W, Han L, Li Q, Wang R, et al. The critical role of tumor size in predicting prognosis for T1 colon cancer. Oncologist. 2019;25(3):244–51.CrossRefPubMedPubMedCentral
7.
go back to reference Zhou L, Li W, Cai S, Yang C, Liu Y, Lin Z. Large tumor size is a poor prognostic factor of gastric cancer with signet ring cell: Results from the surveillance, epidemiology, and end results database. Medicine (Baltimore). 2019;98(40):e17367. Zhou L, Li W, Cai S, Yang C, Liu Y, Lin Z. Large tumor size is a poor prognostic factor of gastric cancer with signet ring cell: Results from the surveillance, epidemiology, and end results database. Medicine (Baltimore). 2019;98(40):e17367.
8.
go back to reference Deng J, Zhang R, Pan Y, Ding X, Cai M, Liu Y, et al. Tumor size as a recommendable variable for accuracy of the prognostic prediction of gastric cancer: a retrospective analysis of 1,521 patients. Ann Surg Oncol. 2015;22(2):565–72.CrossRefPubMed Deng J, Zhang R, Pan Y, Ding X, Cai M, Liu Y, et al. Tumor size as a recommendable variable for accuracy of the prognostic prediction of gastric cancer: a retrospective analysis of 1,521 patients. Ann Surg Oncol. 2015;22(2):565–72.CrossRefPubMed
9.
go back to reference Wang HM, Huang CM, Zheng CH, Li P, Xie JW, Wang JB, et al. Tumor size as a prognostic factor in patients with advanced gastric cancer in the lower third of the stomach. World J Gastroenterol. 2012;18(38):5470–5.CrossRefPubMedPubMedCentral Wang HM, Huang CM, Zheng CH, Li P, Xie JW, Wang JB, et al. Tumor size as a prognostic factor in patients with advanced gastric cancer in the lower third of the stomach. World J Gastroenterol. 2012;18(38):5470–5.CrossRefPubMedPubMedCentral
10.
go back to reference Lu J, Huang CM, Zheng CH, Li P, Xie JW, Wang JB, et al. Consideration of tumor size improves the accuracy of TNM predictions in patients with gastric cancer after curative gastrectomy. Surg Oncol. 2013;22(3):167–71.CrossRefPubMed Lu J, Huang CM, Zheng CH, Li P, Xie JW, Wang JB, et al. Consideration of tumor size improves the accuracy of TNM predictions in patients with gastric cancer after curative gastrectomy. Surg Oncol. 2013;22(3):167–71.CrossRefPubMed
11.
go back to reference Zhao LY, Zhang WH, Chen XZ, Yang K, Chen XL, Liu K, et al. Prognostic significance of tumor size in 2405 patients with gastric cancer: a retrospective cohort study. Medicine (Baltimore). 2015;94(50):e2288. Zhao LY, Zhang WH, Chen XZ, Yang K, Chen XL, Liu K, et al. Prognostic significance of tumor size in 2405 patients with gastric cancer: a retrospective cohort study. Medicine (Baltimore). 2015;94(50):e2288.
12.
13.
go back to reference Zhang PF, Du ZD, Wen F, Zhang FY, Zhang WH, Luo L, et al. Development and validation of a nomogram for predicting overall survival of gastric cancer patients after D2R0 resection. Eur J Cancer Care (Engl). 2020;29(5):e13260. Zhang PF, Du ZD, Wen F, Zhang FY, Zhang WH, Luo L, et al. Development and validation of a nomogram for predicting overall survival of gastric cancer patients after D2R0 resection. Eur J Cancer Care (Engl). 2020;29(5):e13260.
14.
go back to reference Jiang Y, Li T, Liang X, Hu Y, Huang L, Liao Z, et al. Association of adjuvant chemotherapy with survival in patients with stage II or III gastric cancer. JAMA Surg. 2017;152(7):e171087. Jiang Y, Li T, Liang X, Hu Y, Huang L, Liao Z, et al. Association of adjuvant chemotherapy with survival in patients with stage II or III gastric cancer. JAMA Surg. 2017;152(7):e171087.
15.
go back to reference Liang YX, Deng JY, Guo HH, Ding XW, Wang XN, Wang BG, et al. Characteristics and prognosis of gastric cancer in patients aged >/= 70 years. World J Gastroenterol. 2013;19(39):6568–78.CrossRefPubMedPubMedCentral Liang YX, Deng JY, Guo HH, Ding XW, Wang XN, Wang BG, et al. Characteristics and prognosis of gastric cancer in patients aged >/= 70 years. World J Gastroenterol. 2013;19(39):6568–78.CrossRefPubMedPubMedCentral
17.
go back to reference Liu X, Xu Y, Long Z, Zhu H, Wang Y. Prognostic significance of tumor size in T3 gastric cancer. Ann Surg Oncol. 2009;16(7):1875–82.CrossRefPubMed Liu X, Xu Y, Long Z, Zhu H, Wang Y. Prognostic significance of tumor size in T3 gastric cancer. Ann Surg Oncol. 2009;16(7):1875–82.CrossRefPubMed
18.
go back to reference Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–44.CrossRefPubMed Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–44.CrossRefPubMed
19.
go back to reference Hsieh FJ, Wang YC, Hsu JT, Liu KH, Yeh CN. Clinicopathological features and prognostic factors of gastric cancer patients aged 40 years or younger. J Surg Oncol. 2012;105(3):304–9.CrossRefPubMed Hsieh FJ, Wang YC, Hsu JT, Liu KH, Yeh CN. Clinicopathological features and prognostic factors of gastric cancer patients aged 40 years or younger. J Surg Oncol. 2012;105(3):304–9.CrossRefPubMed
20.
go back to reference Borie F, Rigau V, Fingerhut A, Millat B, French Association for Surgical R. Prognostic factors for early gastric cancer in France: cox regression analysis of 332 cases. World J Surg. 2004;28(7):686–91.CrossRefPubMed Borie F, Rigau V, Fingerhut A, Millat B, French Association for Surgical R. Prognostic factors for early gastric cancer in France: cox regression analysis of 332 cases. World J Surg. 2004;28(7):686–91.CrossRefPubMed
21.
go back to reference Yamamura Y, Nakajima T, Ohta K, Nashimoto A, Arai K, Hiratsuka M, et al. Determining prognostic factors for gastric cancer using the regression tree method. Gastric Cancer. 2002;5(4):201–7.CrossRefPubMed Yamamura Y, Nakajima T, Ohta K, Nashimoto A, Arai K, Hiratsuka M, et al. Determining prognostic factors for gastric cancer using the regression tree method. Gastric Cancer. 2002;5(4):201–7.CrossRefPubMed
22.
go back to reference Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449–61.CrossRefPubMedPubMedCentral Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449–61.CrossRefPubMedPubMedCentral
23.
go back to reference Xu M, Huang CM, Zheng CH, Li P, Xie JW, Wang JB, et al. Does tumor size improve the accuracy of prognostic predictions in node-negative gastric cancer (pT1-4aN0M0 stage)? PLoS ONE. 2014;9(7):e101061. Xu M, Huang CM, Zheng CH, Li P, Xie JW, Wang JB, et al. Does tumor size improve the accuracy of prognostic predictions in node-negative gastric cancer (pT1-4aN0M0 stage)? PLoS ONE. 2014;9(7):e101061.
24.
go back to reference Goto A, Nishikawa J, Hideura E, Ogawa R, Nagao M, Sasaki S, et al. Lymph node metastasis can be determined by just tumor depth and lymphovascular invasion in early gastric cancer patients after endoscopic submucosal dissection. Eur J Gastroenterol Hepatol. 2017;29(12):1346–50.CrossRefPubMedPubMedCentral Goto A, Nishikawa J, Hideura E, Ogawa R, Nagao M, Sasaki S, et al. Lymph node metastasis can be determined by just tumor depth and lymphovascular invasion in early gastric cancer patients after endoscopic submucosal dissection. Eur J Gastroenterol Hepatol. 2017;29(12):1346–50.CrossRefPubMedPubMedCentral
25.
go back to reference Holscher AH, Drebber U, Monig SP, Schulte C, Vallbohmer D, Bollschweiler E. Early gastric cancer: lymph node metastasis starts with deep mucosal infiltration. Ann Surg. 2009;250(5):791–7.CrossRefPubMed Holscher AH, Drebber U, Monig SP, Schulte C, Vallbohmer D, Bollschweiler E. Early gastric cancer: lymph node metastasis starts with deep mucosal infiltration. Ann Surg. 2009;250(5):791–7.CrossRefPubMed
26.
go back to reference Chen J, Zhao G, Wang Y. Analysis of lymph node metastasis in early gastric cancer: a single institutional experience from China. World J Surg Oncol. 2020;18(1):57.CrossRefPubMedPubMedCentral Chen J, Zhao G, Wang Y. Analysis of lymph node metastasis in early gastric cancer: a single institutional experience from China. World J Surg Oncol. 2020;18(1):57.CrossRefPubMedPubMedCentral
27.
go back to reference Zhou C, Wang Y, Ji MH, Tong J, Yang JJ, Xia H. Predicting peritoneal metastasis of gastric cancer patients based on machine learning. Cancer Control. 2020;27(1):1073274820968900.CrossRefPubMedPubMedCentral Zhou C, Wang Y, Ji MH, Tong J, Yang JJ, Xia H. Predicting peritoneal metastasis of gastric cancer patients based on machine learning. Cancer Control. 2020;27(1):1073274820968900.CrossRefPubMedPubMedCentral
28.
go back to reference Wang BB, Liu CG, Lu P, Latengbaolide A, Lu Y. Log-normal censored regression model detecting prognostic factors in gastric cancer: a study of 3018 cases. World J Gastroenterol. 2011;17(23):2867–72.PubMedPubMedCentral Wang BB, Liu CG, Lu P, Latengbaolide A, Lu Y. Log-normal censored regression model detecting prognostic factors in gastric cancer: a study of 3018 cases. World J Gastroenterol. 2011;17(23):2867–72.PubMedPubMedCentral
30.
go back to reference Zhang X, Wang Y, Qu P, Liu-Helmersson J, Zhao L, Zhang L, et al. Prognostic value of tumor length for cause-specific death in Resectable esophageal cancer. Ann Thorac Surg. 2018;106(4):1038–46.CrossRefPubMed Zhang X, Wang Y, Qu P, Liu-Helmersson J, Zhao L, Zhang L, et al. Prognostic value of tumor length for cause-specific death in Resectable esophageal cancer. Ann Thorac Surg. 2018;106(4):1038–46.CrossRefPubMed
32.
go back to reference Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1–21.CrossRef Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1–21.CrossRef
34.
go back to reference Takagane A, Terashima M, Abe K, Araya M, Irinoda T, Yonezawa H, et al. Evaluation of the ratio of lymph node metastasis as a prognostic factor in patients with gastric cancer. Gastric Cancer. 1999;2(2):122–8.CrossRefPubMed Takagane A, Terashima M, Abe K, Araya M, Irinoda T, Yonezawa H, et al. Evaluation of the ratio of lymph node metastasis as a prognostic factor in patients with gastric cancer. Gastric Cancer. 1999;2(2):122–8.CrossRefPubMed
35.
go back to reference Zheng D, Chen B, Shen Z, Gu L, Wang X, Ma X, et al. Prognostic factors in stage I gastric cancer: a retrospective analysis. Open Med (Wars). 2020;15(1):754–62.CrossRefPubMed Zheng D, Chen B, Shen Z, Gu L, Wang X, Ma X, et al. Prognostic factors in stage I gastric cancer: a retrospective analysis. Open Med (Wars). 2020;15(1):754–62.CrossRefPubMed
36.
go back to reference Hyung WJ, Noh SH, Yoo CH, Huh JH, Shin DW, Lah KH, et al. Prognostic significance of metastatic lymph node ratio in T3 gastric cancer. World J Surg. 2002;26(3):323–9.CrossRefPubMed Hyung WJ, Noh SH, Yoo CH, Huh JH, Shin DW, Lah KH, et al. Prognostic significance of metastatic lymph node ratio in T3 gastric cancer. World J Surg. 2002;26(3):323–9.CrossRefPubMed
37.
go back to reference Sekiguchi M, Oda I, Taniguchi H, Suzuki H, Morita S, Fukagawa T, et al. Risk stratification and predictive risk-scoring model for lymph node metastasis in early gastric cancer. J Gastroenterol. 2016;51(10):961–70.CrossRefPubMed Sekiguchi M, Oda I, Taniguchi H, Suzuki H, Morita S, Fukagawa T, et al. Risk stratification and predictive risk-scoring model for lymph node metastasis in early gastric cancer. J Gastroenterol. 2016;51(10):961–70.CrossRefPubMed
38.
go back to reference Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA. 2017;318(14):1377–84.CrossRefPubMed Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA. 2017;318(14):1377–84.CrossRefPubMed
39.
go back to reference Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157–72 discussion 207–12.CrossRefPubMed Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157–72 discussion 207–12.CrossRefPubMed
40.
41.
go back to reference Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 2019;39(1):10.CrossRefPubMed Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 2019;39(1):10.CrossRefPubMed
Metadata
Title
Tumor size as a significant prognostic factor in T1 gastric cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis
Authors
Xueyan Xiao
Beibei Gao
Suya Pang
Zeyu Wang
Weiwei Jiang
Weijun Wang
Rong Lin
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02737-z

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.